FrancophonIA/ELRC3.0 huggingface dataset:
English: In the study of patients undergoing peritoneal dialysis, the patients receiving Renagel had similar falls in phosphate as the patients receiving calcium acetate (0.52 and 0.58 mmol/l, respectively).
Slovenian: V študiji z bolniki, ki so prejemali peritonealno dializo, je bilo pri bolnikih, ki so prejemali zdravilo Renagel, ugotovljeno podobno znižanje koncentracije fosfatov kot pri bolnikih, ki so prejemali kalcijev acetat (0,52 oziroma 0,58 mmol/l).
English: What is the risk associated with Renagel?
Slovenian: Kakšna tveganja so povezana z zdravilom Renagel?
English: In peritoneal dialysis, there has been one study comparing Renagel with calcium acetate in 143 patients over 12 weeks.
Slovenian: Pri peritonealni dializi so v eni študiji zdravilo 12 tednov primerjali s kalcijevim acetatom pri 143 bolnikih.
English: Why has Renagel been approved?
Slovenian: Zakaj je bilo zdravilo Renagel odobreno?
English: The first study compared Renagel with calcium acetate (another phosphate-lowering medicine) in 84 patients.
Slovenian: V prvi študiji so zdravilo primerjali s kalcijevim acetatom (drugim zdravilom za zniževanje koncentracije fosfatov) pri 84 bolnikih.
English: Renagel produced a significant decrease in serum phosphate in all of the studies.
Slovenian: Zdravilo Renagel je v vseh študijah povzročilo bistveno znižanje koncentracije fosfatov v serumu.
English: For the full list of all side effects reported with Renagel, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Renagel, glejte navodilo za uporabo.
English: Renagel is a medicine that contains the active substance sevelamer hydrochloride.
Slovenian: Renagel je zdravilo, ki vsebuje zdravilno učinkovino sevelamerijev hidroklorid.
English: Renagel is used to control hyperphosphataemia (high blood phosphate levels) in adults on dialysis (a blood clearance technique used in patients with kidney disease).
Slovenian: Zdravilo Renagel se uporablja za uravnavanje hiperfosfatemije (visoke koncentracije fosfatov v krvi) pri odraslih osebah na dializi (tehniki čiščenja krvi pri bolnikih z obolenjem ledvic).
English: Renagel sevelamer hydrochloride
Slovenian: Renagel sevelamerijev hidroklorid
English: Patients taking Renagel had a similar fall in phosphate levels in the second study.
Slovenian: Pri bolnikih, ki so jemali zdravilo Renagel, je bilo v drugi študiji ugotovljeno podobno znižanje koncentracije fosfatov.
English: Renagel must not be used in people with hypophosphataemia (low blood phosphate levels) or with bowel obstruction (a blockage in the gut).
Slovenian: Zdravila se ne sme uporabljati pri ljudeh s hipofosfatemijo (nizko koncentracijo fosfatov v krvi) ali zaporo črevesa.
English: How does Renagel work?
Slovenian: Kako zdravilo Renagel deluje?
English: What is Renagel?
Slovenian: Kaj je zdravilo Renagel?
English: How has Renagel been studied?
Slovenian: Kako je bilo zdravilo Renagel raziskano?
English: The active substance in Renagel, sevelamer hydrochloride, is a phosphate binder.
Slovenian: Zdravilna učinkovina zdravila Renagel je fosfatni vezalec sevelamerijev hidroklorid.
English: What is Renagel used for?
Slovenian: Za kaj se zdravilo Renagel uporablja?
English: How is Renagel used?
Slovenian: Kako se zdravilo Renagel uporablja?
English: List of the names, pharmaceutical forms, strength of the medicinal product, route of administration, marketing authorisation holder in the Member States
Slovenian: Seznam imen, farmacevtskih oblik, jakosti zdravila, poti uporabe zdravila in imetnikov dovoljenj za promet z zdravilom v državah članicah
English: Pharmaceutical form Route of administration
Slovenian: Farmacevtska oblika Pot uporabe
English: Goserelin Novosis 3,6 mg Implantat implant, pre-filled syringe subcutaneous use
Slovenian: Goserelin Novosis 3,6 mg Implantat implantat, napolnjena injekcijska brizga
English: 50 ml (10 mg/ml) 1 vial
Slovenian: 50 ml (10 mg/ml) 1 viala
English: Date of opening:____________
Slovenian: Datum odprtja:_________________
English: - The other ingredients are:
Slovenian: - Druge sestavine so:
English: Pregnancy and Postpartum During the second and third trimesters of pregnancy:
Slovenian: Nosečnost in poporodno obdobje Drugo in tretje trimesečje nosečnosti:
English: It is important to note that at time of the 96-week analysis, 48 % of patients overall remained on study.
Slovenian: Omeniti je treba, da je bilo v študiji v času analize po 96 tednih v celoti še 48 % bolnikov.
English: Typically, such reactions have been observed within the first few weeks or months of initiation of CART.
Slovenian: Take reakcije so navadno opazili v prvih nekaj tednih ali mesecih po uvedbi
English: You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Slovenian: O neželenih učinkih lahko poročate tudi neposredno na nacionalni center za poročanje, ki je naveden v Prilogi V: S tem, ko poročate o neželenih učinkih, lahko prispevate k zagotovitvi več informacij o varnosti tega zdravila.
English: If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Slovenian: Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom ali farmacevtom preden vzamete to zdravilo.
English: Frequency is defined using the following convention: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000).
Slovenian: Pogostnost neželenih učinkov je opredeljena v skladu z naslednjim dogovorom: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000).
English: PHARMACEUTICAL FORM AND CONTENTS Hard capsule
Slovenian: FARMACEVTSKA OBLIKA IN VSEBINA trda kapsula
English: Per protocol analysise
Slovenian: Analiza po protokolu e
English: Switching to capsules from other formulations is encouraged as soon as patients are able to consistently swallow capsules.
Slovenian: Prehod z zdravljenja z drugimi formulacijami na zdravljenje s kapsulami je priporočljiv takoj, ko lahko bolniki kapsule zanesljivo pogoltnejo.
English: Difference estimatee [95% CI]
Slovenian: Ocenjena razlika [95 % IZ]
English: Efficacy Outcomes at Week 48a and at Week 96 (Study 045)
Slovenian: Preglednica 6: Izidi učinkovitosti v 48. tednu in 96. tednu (študija 045)
English: The rash usually disappears within 2 weeks without any change to your atazanavir treatment.
Slovenian: Izpuščaj običajno izzveni v 2 tednih brez kakršne koli spremembe zdravljenja z atazanavirjem.
English: If you have been told by your doctor that you have an intolerance to some sugars (e.g. lactose), contact your doctor before taking this medicinal product.
Slovenian: Če vam je zdravnik povedal, da ne prenašate nekaterih sladkorjev (npr. laktoze), se pred uporabo tega zdravila posvetujte z zdravnikom.
English: b Cmin is concentration 24 hours post-dose
Slovenian: b Cmin je koncentracija 24 ur po uporabi odmerka.
English: The fluticasone propionate plasma levels increased significantly, whereas the intrinsic cortisol levels decreased by approximately 86% (90% confidence interval 82%89%).
Slovenian: Plazemske vrednosti flutikazonpropionata so se znatno povečale, intrinzične vrednosti kortizola pa zmanjšale za približno 86% (90% interval zaupanja; 82-89%).
English: TAD Pharma GmbH Heinz-Lohmann-Straße 5 27472 Cuxhaven Germany
Slovenian: TAD Pharma GmbH Heinz-Lohmann-Straße 5 27472 Cuxhaven
English: Atazanavir Krka capsules may be used by adults and children 6 years of age and older.
Slovenian: Kapsule Atazanavir Krka lahko uporabljajo odrasli in otroci, stari 6 let in več.
English: 90 (3 x 30) hard capsules
Slovenian: 90 (3 x 30) trdih kapsul
English: If you feel dizzy or lightheaded, do not drive or use machines and contact your doctor immediately.
Slovenian: Če občutite omotico ali vrtoglavico, ne vozite vozil ali upravljajte strojev in se takoj posvetujte z zdravnikom.
English: Tell your doctor if you notice anything unusual about your health.
Slovenian: če ste opazili kar koli neobičajnega glede vašega zdravstvenega stanja..
English: Consult the dosing table for the specific formulation (see Summary of Product Characteristics for other formulations).
Slovenian: Glejte tabelo za odmerjanje posamezne farmacevtske oblike (glejte povzetek glavnih značilnosti za druge formulacije).
English: The clinical data derived from this study are inadequate to support the use of atazanavir capsules (with or without ritonavir) in children below 6 years of age.
Slovenian: Klinični podatki iz te študije niso zadostni, da bi podprli uporabo atazanavirja (z ritonavirjem ali brez njega) pri otrocih, mlajših od 6 let.
English: Pharmacotherapeutic group: antivirals for systemic use, protease inhibitors, ATC code: J05AE08.
Slovenian: Farmakoterapevtska skupina: zdravila za sistemsko zdravljenje virusnih infekcij, zaviralci proteaz, oznaka ATC: J05AE08.
English: Week 48: 1.7% [-3.8%, 7.1%] Week 96: 6.1% [0.3%, 12.0%]
Slovenian: 48. teden: 1,7 % [-3,8 %, 7,1 %] 96. teden: 6,1 % [0,3 %, 12,0 %]
English: Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucosegalactose malabsorption should not take this medicine.
Slovenian: Bolniki z redko dedno intoleranco za galaktozo, odsotnostjo encima laktaze ali malabsorpcijo glukoze/galaktoze ne smejo jemati tega zdravila.
English: Your doctor has prescribed Atazanavir Krka for you because you are infected by the HIV that causes Acquired Immunodeficiency Syndrome (AIDS).
Slovenian: Zdravnik vam je predpisal zdravilo Atazanavir Krka, ker ste okuženi s HIV, ki povzroča sindrom pridobljene imunske pomanjkljivosti (AIDS).
English: Table 2: Interactions between atazanavir and other medicinal products Medicinal products by therapeutic area
Slovenian: Preglednica 2: Interakcije med atazanavirjem in drugimi zdravili Zdravila po terapevtskih področjih
English: In this way Atazanavir Krka reduces the risk of developing illnesses linked to HIV infection.
Slovenian: Na ta način zdravilo Atazanavir Krka zmanjša tveganje, da bi se razvile bolezni, ki so povezane z okužbo s HIV.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation:
Slovenian: Datum prve pridobitve dovoljenja za promet:
English: Assessment of the pharmacokinetics, safety, tolerability, and efficacy of atazanavir is based on data from the open-label, multicenter clinical trial AI424-020 conducted in patients from 3 months to 21 years of age.
Slovenian: Pediatrična populacija Ocena farmakokinetike, varnosti, prenašanja zdravila s strani bolnikov in učinkovitosti atazanavirja temelji na podatkih iz odprtega, multicentričnega kliničnega preskušanja AI424-020, ki je bilo izvedeno pri bolnikih, starih od 3 mesece do 21 let.
English: (See section 4.4 Withdrawal of ritonavir only under restrictive conditions).
Slovenian: (Glejte poglavje 4.4 Odtegnitev ritonavirja le v omejenih pogojih.)
English: Following a possible decrease in atazanavir exposure during the second and third trimester, atazanavir exposures might increase during the first two months after delivery (see section 5.2).
Slovenian: Po morebitnem zmanjšanju izpostavljenosti atazanavirju med drugim in tretjim trimesečjem nosečnosti, se lahko izpostavljenost atazanavirju poveča v prvih dveh mesecih po porodu (glejte poglavje 5.2).
English: Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and Pneumocystis jirovecii pneumonia.
Slovenian: Pomembni primeri so citomegalovirusni retinitis, generalizirane in/ali žariščne okužbe z mikobakterijami in s Pneumocystis jirovecii povzročena pljučnica.
English: Paediatric patients (at least 3 months of age and weighing at least 5 kg):
Slovenian: Pediatrični bolniki (stari najmanj 3 mesece in s telesno maso najmanj 5 kg):
English: Other interactions Interactions between atazanavir and other medicinal products are listed in the table below (increase is indicated as “↑”, decrease as “↓”, no change as “↔”).
Slovenian: V spodnji preglednici so navedene interakcije med atazanavirjem in drugimi zdravili (zvišanje je navedeno kot “↑”, znižanje kot “↓”, brez spremembe kot “↔”).
English: SEDATIVES Benzodiazepines Midazolam Triazolam
Slovenian: SEDATIVI Benzodiazepini Midazolam Triazolam
English: As a result, greater peak to trough ratios are observed; however at recommended doses, geometric mean atazanavir exposures (cmin, cmax and AUC) in paediatric patients are expected to be similar to those observed in adults.
Slovenian: Posledično so opažali večje razmerje med največjo in najmanjšo koncentracijo, vendar pa se pri priporočenih odmerkih pričakuje, da bo geometrična srednja izpostavljenost atazanavirju (Cmin, Cmax in AUC) pri pediatričnih bolnikih podobna kot pri odraslih.
English: 50 to <100 cells/mm3
Slovenian: 50 to < 100 celic/mm3
English: - Changes in the way your heart beats (heart rhythm change) may occasionally happen.
Slovenian: - Občasno lahko pride do sprememb srčnega utripa (sprememba srčnega ritma).
English: 15 to less than 35 At least 35
Slovenian: 15 do manj kot 35 najman 35
English: The primary endpoint was the time-averaged difference in change from baseline in HIV RNA through 48 weeks (Table 6).
Slovenian: Primarni opazovani dogodek je bil časovno povprečna razlika v spremembi vrednosti HIV RNA po 48 tednih od izhodišča (preglednica 6).
English: Although not studied, there is a potential for an increase in pravastatin or fluvastatin exposure when co- administered with protease inhibitors.
Slovenian: Čeprav ni bilo raziskovano, obstaja možnost za povečano izpostavljenost pravastatinu ali fluvastatinu ob sočasni uporabi z zaviralci proteaz.
English: If you have liver problems, including hepatitis B or C infection, you may experience a worsening of your liver problems.
Slovenian: vključno z hepatitisom B ali C, se težave z jetri lahko poslabšajo.
English: Atazanavir should not be used in combination with medicinal products that are substrates of CYP3A4 and have a narrow therapeutic index.
Slovenian: Atazanavir se ne sme uporabljati skupaj z zdravili, ki so substrati za CYP3A4 in imajo ozek terapevtski indeks.
English: Atazanavir Krka 300 mg with ritonavir 100 mg may not provide sufficient exposure to atazanavir, especially when the activity of atazanavir or the whole regimen may be compromised due to drug resistance.
Slovenian: Uporaba zdravila Atazanavir Krka 300 mg z ritonavirjem 100 mg morda ne bo zagotovila ustrezne izpostavljenosti atazanavirju, še posebej kadar je učinkovitost atazanavirja ali celotnega režima zdravljenja ogrožena zaradi odpornosti na zdravilo.
English: - if you have moderate to severe liver problems.
Slovenian: - če imate zmerno do hudo okvaro jeter.
English: Shelf life after first opening is 2 months, stored below 25°C.
Slovenian: Rok uporabnosti po prvem odprtju je 2 meseca, če je zdravilo shranjeno pri temperaturi do 25 °C.
English: - Liver problems may uncommonly happen.
Slovenian: - Občasno lahko pride do težav z jetri.
English: 100 to <200 cells/mm
Slovenian: 100 to < 200 celic/mm
English: It is important that you take Atazanavir Krka with food (a meal or a substantial snack) as this helps the body absorb the medicine.
Slovenian: Pomembno je, da zdravilo Atazanavir Krka jemljete skupaj s hrano (med kosilom ali z obilnejšim obrokom) in tako telesu olajšate absorpcijo zdravila.
English: Atazanavir should be administered 2 hours before or 1 hour after antacids or buffered medicinal products.
Slovenian: Atazanavir je treba uporabljati 2 uri pred ali 1 uro po uporabi antacida ali zdravila, ki vsebuje pufer.
English: It is not known whether atazanavir with ritonavir administered to the mother during pregnancy will exacerbate physiological hyperbilirubinaemia and lead to kernicterus in neonates and infants.
Slovenian: Ni znano, ali lahko atazanavir z ritonavirjem, če ga jemljejo nosečnice, poslabša fiziološko hiperbilirubinemijo in pri novorojenčkih in dojenčkih povzroči kernikterus.
English: b Ten patients had baseline phenotypic resistance to atazanavir + ritonavir (fold change [FC]>5.2).
Slovenian: b Deset bolnikov je v izhodišču imelo fenotipsko odpornost na atazanavir + ritonavir (razmerje spremembe (“fold change” [FC]) > 5,2).
English: Given that low dose ritonavir (100 mg twice daily) has been shown to have no significant effect on methadone concentrations, no interaction is expected if methadone is co- administered with atazanavir, based on these data.
Slovenian: Glede na to, da je bilo dokazano, da nizki odmerek ritonavirja (100 mg dvakrat na dan) nima pomembnega vpliva na koncentracije metadona, na osnovi teh podatkov pri sočasni uporabi metadona z atazanavirjem interakcij ne pričakujemo.
English: ALPHA 1-ADRENORECEPTOR ANTAGONIST Alfuzosin
Slovenian: ANTAGONISTI ADRENERGIČNIH RECEPTORJEV ALFA-1
English: The mechanism of interaction between atazanavir and tenofovir disoproxil fumarate is unknown.
Slovenian: Mehanizem interakcije med atazanavirjem in dizoproksiltenofovirjevim fumaratom ni znan.
English: Number of patients with paired genotypes classified as virological failures (HIV RNA ≥ 400 copies/ml).
Slovenian: a Število bolnikov s pari genotipov, označenimi kot virusni neodziv (HIV RNA ≥ 400 kopij/ml).
English: Efficacy Atazanavir/ritonavir is not effective in viral strains harbouring multiple mutations of resistance.
Slovenian: Učinkovitost Atazanavir/ritonavir ni učinkovit pri virusnih sevih, pri katerih je prisotnih več mutacij, ki vodijo v odpornost.
English: (indigestion) - fatigue (extreme tiredness)
Slovenian: - izčrpanost (močna utrujenost).
English: that co-administration with famotidine is not recommended but if required, atazanavir without ritonavir should be administered either 2 hours after famotidine or 12 hours before.
Slovenian: - sočasna uporaba s famotidinom ni priporočljiva, če pa je potrebna, mora bolnik atazanavir brez ritonavirja vzeti 2 uri po famotidinu ali 12 ur pred famotidinom.
English: Capsules should be swallowed whole.
Slovenian: Kapsule je treba pogoltniti cele.
English: Capsule contents: lactose monohydrate, crospovidone (type A) and magnesium stearate.
Slovenian: Vsebina kapsule: laktoza monohidrat, krospovidon (vrsta A) in magnezijev stearat.
English: The withdrawal of ritonavir from the boosted regimen of Atazanavir Krka is not recommended, but may be considered in adults patients at the dose of 400 mg once daily with food only under the following combined restrictive conditions: - absence of prior virologic failure - undetectable viral load during the last 6 months under current regimen - viral strains not harbouring HIV resistance associated mutations (RAMs) to current regimen.
Slovenian: Odtegnitev ritonavirja iz okrepljenega režima zdravljenja z zdravilom Atazanavir Krka ni priporočljiva, se pa o njej lahko razmisli pri odraslih bolnikih pri uporabi odmerka 400 mg enkrat na dan skupaj s hrano, vendar le ob upoštevanju vseh naslednjih omejitvenih pogojev: - odsotnost predhodnega virusnega neodziva, - nedokazljivo virusno breme v zadnjih 6 mesecih pri trenutnem režimu zdravljenja, - virusni sevi ne vsebujejo mutacij, povezanih z odpornostjo virusa HIV (RAM; “resistance associated mutations”) proti trenutnemu režimu zdravljenja.
English: ERECTILE DYSFUNCTION PDE5 Inhibitors Sildenafil, tadalafil, vardenafil
Slovenian: ZDRAVILA ZA ZDRAVLJENJE EREKTILNE DISFUNKCIJE Zaviralci PDE5 Sildenafil, tadalafil, vardenafil
English: Particular caution should be used when prescribing Atazanavir Krka in association with medicinal products which have the potential to increase the QT interval and/or in patients with pre-existing risk factors (bradycardia, long congenital QT, electrolyte imbalances (see sections 4.8 and 5.3).
Slovenian: Posebna previdnost je potrebna pri predpisovanju zdravila Atazanavir Krka skupaj z zdravili, ki lahko podaljšajo interval QT, in/ali pri bolnikih z že obstoječimi dejavniki tveganja (bradikardija, prirojeno podaljšanje intervala QT, neravnovesje elektrolitov) (glejte poglavji 4.8 in 5.3).
English: Assessment of adverse reactions for atazanavir is based on safety data from clinical studies and postmarketing experience.
Slovenian: Pregled neželenih učinkov v preglednici Ocena neželenih učinkov atazanavirja temelji na podatkih o varnosti zdravila, pridobljenih iz kliničnih preskušanj in iz izkušenj v obdobju trženja zdravila.
English: Cmax ng/mL Geometric mean (CV%) AUC ng•h/mL Geometric mean (CV%)
Slovenian: Cmax ng/ml geometrična sredina (KV %) AUC ng•h/ml geometrična sredina (KV %)
English: While effective viral suppression with antiretroviral therapy has been proven to substantially reduce the risk of sexual transmission, a residual risk cannot be excluded.
Slovenian: 4.4 Posebna opozorila in previdnostni ukrepi Čeprav se je izkazalo, da učinkovita virusna supresija s protiretrovirusno terapijo bistveno zmanjša tveganje spolnega prenosa, preostalega tveganja ni mogoče izključiti.
English: Atazanavir Krka with food and drink
Slovenian: Zdravilo Atazanavir Krka skupaj s hrano in pijačo
English: Co-administration with a high-fat meal did not affect the AUC of atazanavir relative to fasting conditions and the cmax was within 11% of fasting values.
Slovenian: Uporaba skupaj z obrokom, bogatim z maščobami, ni vplivala na vrednost AUC atazanavirja v primerjavi z uporabo na tešče, vrednost Cmax pa je ostala znotraj 11 % vrednosti na tešče.
English: ≥100,000 copies/ml
Slovenian: ≥ 100.000 kopij/ml
English: Atazanavir, simultaneous administration with ddI+d4T (fasted)
Slovenian: Atazanavir, sočasna uporaba z ddI+d4T
English: This co-administration might be considered on a case by case basis if deemed necessary, in patients with suppressed HIV viral loads and with HIV viral strain without any suspected resistance to the HIV regimen.
Slovenian: sočasni uporabi, če je le-ta potrebna, je smiselno razmisliti pri vsakem posameznem bolniku z nadzorovanim bremenom virusa HIV in z okužbo s sevi virusa HIV, ki niso odporni na režim zdravljenja.
English: Fifteen of 120 (13%) patients in the atazanavir + ritonavir treatment arm and 17 of 123 (14%) patients in the lopinavir + ritonavir arm had four or more of the PI substitutions L10, M46, I54, V82, I84, and L90.
Slovenian: Petnajst od 120 (13 %) bolnikov v skupini z atazanavirjem + ritonavirjem in 17 od 123 (14 %) bolnikov v skupini z lopinavirjem + ritonavirjem je imelo štiri ali več substitucij zaviralca proteaz L10, M46, I54, V82,
English: Atazanavir Krka given without ritonavir should not be used in pregnant patients given that it could result of suboptimal exposure of particular concern for the mother infection and vertical transmission.
Slovenian: Zdravilo Atazanavir Krka brez ritonavirja se ne sme uporabljati pri nosečnicah, saj možna suboptimalna izpostavljenost predstavlja pomembno tveganje za okužbo matere in vertikalni prenos.
English: 2 years
Slovenian: 6.3 Rok uporabnosti 2 leti
English: Atazanavir is an azapeptide HIV-1 protease inhibitor (PI).
Slovenian: Mehanizem delovanja Atazanavir je azapeptidni zaviralec proteaz (PI) HIV-1.
English: What Atazanavir Krka is and what it is used for What you need to know before you take Atazanavir Krka How to take Atazanavir Krka Possible side effects
Slovenian: Kaj je zdravilo Atazanavir Krka in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Atazanavir Krka Kako jemati zdravilo Atazanavir Krka
English: A dose reduction of the glucocorticoid should be considered with close monitoring of local and systemic effects or a switch to a glucocorticoid, which is not a substrate for CYP3A4 (e.g., beclomethasone).
Slovenian: odmerka glukokortikoida in skrbno nadzirati morebiten pojav lokalnih ali sistemskih učinkov ali glukokortikoid zamenjati s takšnim, ki ni substrat za CYP3A4 (npr. beklometazon).
English: See section 2 "Atazanavir Krka contains lactose monohydrate".
Slovenian: Glejte poglavje 2 "Zdravilo Atazanavir Krka vsebuje laktozo monohidrat ".